Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY22 results · Apr–Jun 2021
Ajanta Pharma reported revenue from operations of ₹747.99 crore (up 11.9% from Q1 FY21) and net profit of ₹173.75 crore (up 17.6% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 747.99 | 668.20 | +11.9% | 756.84 | −1.2% |
| Other income | 32.63 | 13.12 | +148.7% | 2.53 | 13x |
| Total income | 780.62 | 681.32 | +14.6% | 759.37 | +2.8% |
| Profit before tax | 220.45 | 206.69 | +6.7% | 228.78 | −3.6% |
| Net profit for the period | 173.75 | 147.76 | +17.6% | 159.26 | +9.1% |
| EPS, basic (₹) | 20.08 | 16.93 | +18.6% | 18.40 | +9.1% |
| Net margin (%) | 23.2 | 22.1 | 21.0 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 742.72 | 560.85 | +32.4% | 748.07 | −0.7% |
| Other income | 31.00 | 13.10 | +136.6% | 1.33 | 23x |
| Total income | 773.72 | 573.95 | +34.8% | 749.40 | +3.2% |
| Profit before tax | 233.09 | 158.47 | +47.1% | 216.75 | +7.5% |
| Net profit for the period | 193.46 | 115.69 | +67.2% | 154.78 | +25.0% |
| EPS, basic (₹) | 22.36 | 13.26 | +68.6% | 17.89 | +25.0% |
| Net margin (%) | 26.0 | 20.6 | 20.7 |
Consolidated
- Filed with BSE
- 30 Jul 2021, 12:18 IST
- Board meeting
- 29 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2021, 12:18 IST
- Board meeting
- 29 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE